Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-755 continuation study in severe congenital thrombotic thrombocytopenic purpura
2020-003348-10Phase 3Unknown
- Sponsor
- Baxalta
- Start
- Sep 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Apadamtase alfa in Upshaw-Schulman syndrome (USS), sponsored by Baxalta. Primary endpoint: Long-term safety and tolerability. Status: unknown.
02
Drugs
Apadamtase alfa
03
Conditions
Upshaw-Schulman syndrome (USS)
Beyond the preview
Go deeper on 2020-003348-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003348-10.